164 related articles for article (PubMed ID: 38480027)
21. The Preclinical Pharmacology of Tepotinib-A Highly Selective MET Inhibitor with Activity in Tumors Harboring MET Alterations.
Albers J; Friese-Hamim M; Clark A; Schadt O; Walter-Bausch G; Stroh C; Johne A; Karachaliou N; Blaukat A
Mol Cancer Ther; 2023 Jul; 22(7):833-843. PubMed ID: 36999986
[TBL] [Abstract][Full Text] [Related]
22. The c-Met inhibitors: a new class of drugs in the battle against advanced nonsmall-cell lung cancer.
Sgambato A; Casaluce F; Maione P; Rossi A; Rossi E; Napolitano A; Palazzolo G; Bareschino MA; Schettino C; Sacco PC; Ciardiello F; Gridelli C
Curr Pharm Des; 2012; 18(37):6155-68. PubMed ID: 22873759
[TBL] [Abstract][Full Text] [Related]
23. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
Shea M; Costa DB; Rangachari D
Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497
[TBL] [Abstract][Full Text] [Related]
24. Asian Thoracic Oncology Research Group (ATORG) Expert Consensus Statement on MET Alterations in NSCLC: Diagnostic and Therapeutic Considerations.
Ahn MJ; Mendoza MJL; Pavlakis N; Kato T; Soo RA; Kim DW; Liam CK; Hsia TC; Lee CK; Reungwetwattana T; Geater S; Chan OSH; Prasongsook N; Solomon BJ; Nguyen TTH; Kozuki T; Yang JC; Wu YL; Mok TSK; Tan DS; Yatabe Y
Clin Lung Cancer; 2022 Dec; 23(8):670-685. PubMed ID: 36151006
[TBL] [Abstract][Full Text] [Related]
25. The Clinical Impact of Capmatinib in the Treatment of Advanced Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation or Gene Amplification.
Choi W; Park SY; Lee Y; Lim KY; Park M; Lee GK; Han JY
Cancer Res Treat; 2021 Oct; 53(4):1024-1032. PubMed ID: 33540494
[TBL] [Abstract][Full Text] [Related]
26. [MET exon 14 splicing sites mutations: A new therapeutic opportunity in lung cancer].
Baldacci S; Kherrouche Z; Descarpentries C; Wislez M; Dansin E; Furlan A; Tulasne D; Cortot AB
Rev Mal Respir; 2018 Oct; 35(8):796-812. PubMed ID: 30174236
[TBL] [Abstract][Full Text] [Related]
27. Next-generation sequencing of tissue and circulating tumor DNA: Resistance mechanisms to EGFR targeted therapy in a cohort of patients with advanced non-small cell lung cancer.
Zhang Y; Xiong L; Xie F; Zheng X; Li Y; Zhu L; Sun J
Cancer Med; 2021 Jul; 10(14):4697-4709. PubMed ID: 34173341
[TBL] [Abstract][Full Text] [Related]
28. MET alterations and their impact on the future of non-small cell lung cancer (NSCLC) targeted therapies.
Lee M; Jain P; Wang F; Ma PC; Borczuk A; Halmos B
Expert Opin Ther Targets; 2021 Apr; 25(4):249-268. PubMed ID: 33945380
[No Abstract] [Full Text] [Related]
29. [MET Exon 14 Skipping Mutations in Non-small Cell Lung Cancer].
Yin L; Lu Y
Zhongguo Fei Ai Za Zhi; 2018 Jul; 21(7):553-559. PubMed ID: 30037377
[TBL] [Abstract][Full Text] [Related]
30. [Capmatinib in advanced NSCLC for previously treated patients with MET exon 14 skipping mutation].
Basse C; Régaldo-Saint Blancard L
Bull Cancer; 2023 Sep; 110(9):869-871. PubMed ID: 37442707
[No Abstract] [Full Text] [Related]
31. MET-Targeted Therapies and Clinical Outcomes: A Systematic Literature Review.
Dong Y; Xu J; Sun B; Wang J; Wang Z
Mol Diagn Ther; 2022 Mar; 26(2):203-227. PubMed ID: 35266116
[TBL] [Abstract][Full Text] [Related]
32. Capmatinib for the treatment of non-small cell lung cancer.
Vansteenkiste JF; Van De Kerkhove C; Wauters E; Van Mol P
Expert Rev Anticancer Ther; 2019 Aug; 19(8):659-671. PubMed ID: 31368815
[No Abstract] [Full Text] [Related]
33. Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial.
Wu YL; Cheng Y; Zhou J; Lu S; Zhang Y; Zhao J; Kim DW; Soo RA; Kim SW; Pan H; Chen YM; Chian CF; Liu X; Tan DSW; Bruns R; Straub J; Johne A; Scheele J; Park K; Yang JC;
Lancet Respir Med; 2020 Nov; 8(11):1132-1143. PubMed ID: 32479794
[TBL] [Abstract][Full Text] [Related]
34. Targeted therapeutic options in early and metastatic NSCLC-overview.
Gálffy G; Morócz É; Korompay R; Hécz R; Bujdosó R; Puskás R; Lovas T; Gáspár E; Yahya K; Király P; Lohinai Z
Pathol Oncol Res; 2024; 30():1611715. PubMed ID: 38605928
[TBL] [Abstract][Full Text] [Related]
35. Tepotinib in patients with NSCLC harbouring MET exon 14 skipping: Japanese subset analysis from the Phase II VISION study.
Sakai H; Morise M; Kato T; Matsumoto S; Sakamoto T; Kumagai T; Tokito T; Atagi S; Kozuki T; Tanaka H; Chikamori K; Shinagawa N; Takeoka H; Bruns R; Straub J; Schumacher KM; Paik PK
Jpn J Clin Oncol; 2021 Aug; 51(8):1261-1268. PubMed ID: 34037224
[TBL] [Abstract][Full Text] [Related]
36. The role of MET receptor tyrosine kinase in non-small cell lung cancer and clinical development of targeted anti-MET agents.
Robinson KW; Sandler AB
Oncologist; 2013; 18(2):115-22. PubMed ID: 23345546
[TBL] [Abstract][Full Text] [Related]
37. MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression.
Awad MM; Oxnard GR; Jackman DM; Savukoski DO; Hall D; Shivdasani P; Heng JC; Dahlberg SE; Jänne PA; Verma S; Christensen J; Hammerman PS; Sholl LM
J Clin Oncol; 2016 Mar; 34(7):721-30. PubMed ID: 26729443
[TBL] [Abstract][Full Text] [Related]
38. Responses to crizotinib and cabozantinib in patient with lung adenocarcinoma harboring mesenchymal-epithelial transition factor exon 14 skipping mutation: A case report.
Qin RY; Liu LS; Zhang HY; Lu CH; Guo XY; Zhang LY; Yuan XB; Xue HH
Medicine (Baltimore); 2021 Jan; 100(4):e24300. PubMed ID: 33530219
[TBL] [Abstract][Full Text] [Related]
39. Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation.
Baltschukat S; Engstler BS; Huang A; Hao HX; Tam A; Wang HQ; Liang J; DiMare MT; Bhang HC; Wang Y; Furet P; Sellers WR; Hofmann F; Schoepfer J; Tiedt R
Clin Cancer Res; 2019 May; 25(10):3164-3175. PubMed ID: 30674502
[TBL] [Abstract][Full Text] [Related]
40. Clonal MET Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.
Lai GGY; Lim TH; Lim J; Liew PJR; Kwang XL; Nahar R; Aung ZW; Takano A; Lee YY; Lau DPX; Tan GS; Tan SH; Tan WL; Ang MK; Toh CK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Yuan J; Lim TKH; Lim AST; Hillmer AM; Lim WT; Iyer NG; Tam WL; Zhai W; Tan EH; Tan DSW
J Clin Oncol; 2019 Apr; 37(11):876-884. PubMed ID: 30676858
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
